EE05282B1 - strogeeni-tsklodekstriini komplekside kompositsioonid - Google Patents

strogeeni-tsklodekstriini komplekside kompositsioonid

Info

Publication number: EE05282B1
Authority: EE; Estonia
Prior art keywords: compositions; complexes; strogen; clodextrin; dosage forms
Prior art date: 2000-12-20

Application number

EEP200300298A

Other languages

English (en)

Inventor

Backensfeld Thomas

Heil Wolfgang

Lipp Ralph

Original Assignee

Schering Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-20

Filing date

2001-12-20

Publication date

2010-04-15

2001-12-20 Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft

2003-12-15 Publication of EE200300298A publication Critical patent/EE200300298A/et

2010-04-15 Publication of EE05282B1 publication Critical patent/EE05282B1/et

Links

239000000203 mixture Substances 0.000 title abstract 3
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 2
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 2
239000002552 dosage form Substances 0.000 abstract 2
229960002568 ethinylestradiol Drugs 0.000 abstract 2
229920000858 Cyclodextrin Polymers 0.000 abstract 1
METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
229960004845 drospirenone Drugs 0.000 abstract 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Nanotechnology (AREA)
Biophysics (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Materials Engineering (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
Polymers & Plastics (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

EEP200300298A 2000-12-20 2001-12-20 strogeeni-tsklodekstriini komplekside kompositsioonid EE05282B1 (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25648400P	2000-12-20	2000-12-20
EP00610135A EP1216713A1 (en)	2000-12-20	2000-12-20	Compositions of estrogen-cyclodextrin complexes
PCT/IB2001/002605 WO2002049675A1 (en)	2000-12-20	2001-12-20	Compositions of estrogen-cyclodextrin complexes

Publications (2)

Publication Number	Publication Date
EE200300298A EE200300298A (et)	2003-12-15
EE05282B1 true EE05282B1 (et)	2010-04-15

Family

ID=26073713

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300298A EE05282B1 (et)	2000-12-20	2001-12-20	strogeeni-tsklodekstriini komplekside kompositsioonid

Country Status (30)

Country	Link
US (3)	US6958326B2 (et)
EP (3)	EP1216713A1 (et)
JP (2)	JP4782364B2 (et)
KR (3)	KR20080108161A (et)
CN (1)	CN1268396C (et)
AT (1)	ATE311204T1 (et)
AU (3)	AU1941802A (et)
BG (1)	BG66050B1 (et)
BR (1)	BRPI0116417B8 (et)
CA (2)	CA2432151C (et)
CY (2)	CY1106071T1 (et)
CZ (2)	CZ307876B6 (et)
DE (1)	DE60115499T2 (et)
DK (2)	DK1353700T3 (et)
EA (2)	EA011275B1 (et)
EE (1)	EE05282B1 (et)
ES (2)	ES2639537T3 (et)
HK (1)	HK1055397A1 (et)
HR (2)	HRP20030592B1 (et)
HU (2)	HU230299B1 (et)
IL (3)	IL156437A0 (et)
LT (1)	LT1632237T (et)
ME (1)	MEP38108A (et)
MX (1)	MXPA03005636A (et)
NO (1)	NO332726B1 (et)
NZ (1)	NZ526847A (et)
RS (2)	RS57801B1 (et)
SI (2)	SI1353700T1 (et)
SK (1)	SK287500B6 (et)
WO (1)	WO2002049675A1 (et)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6787531B1 (en) *	1999-08-31	2004-09-07	Schering Ag	Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) *	2001-01-11	2002-09-19	Schering Aktiengesellschaft	Drospirenone for hormone replacement therapy
US6992075B2 (en) *	2003-04-04	2006-01-31	Barr Laboratories, Inc.	C(14) estrogenic compounds
EP2260834A2 (en) *	2003-09-03	2010-12-15	Mallinckrodt Inc.	Granular sustained release preparation and production thereof
US8022053B2 (en) *	2004-11-02	2011-09-20	Bayer Schering Pharma Aktiengesellschaft	Oral solid dosage forms containing a low dose of estradiol
UY29527A1 (es)	2005-05-13	2006-12-29	Schering Ag	Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US20070287684A1 (en)	2006-05-22	2007-12-13	Irshad Chaudry	Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
US8617597B2 (en)	2006-07-06	2013-12-31	Bayer Intellectual Property Gmbh	Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh)	2006-07-06	2009-07-22	拜耳先灵医药股份有限公司	用于避孕和预防先天性畸形风险的药物制剂
PT1886694E (pt) *	2006-08-10	2009-08-17	Jenapharm Gmbh	Forma medicamentosa peroral com dienogest e etinilestradiol destinada à contracepção
HUP0700826A3 (en) *	2007-12-20	2010-03-29	Richter Gedeon Nyrt	Coated tablet containing drospirenone and process for producing the same
CN102083418A (zh) *	2008-04-24	2011-06-01	伊万斯彻有限公司	口服避孕药剂及其制备方法
US8735374B2 (en) *	2009-07-31	2014-05-27	Intelgenx Corp.	Oral mucoadhesive dosage form
UY32836A (es)	2009-08-12	2011-03-31	Bayer Schering Pharma Ag	Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
US20110136815A1 (en)	2009-12-08	2011-06-09	Horst Zerbe	Solid oral film dosage forms and methods for making same
US10610528B2 (en)	2009-12-08	2020-04-07	Intelgenx Corp.	Solid oral film dosage forms and methods for making same
JP5852639B2 (ja) *	2010-04-15	2016-02-03	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	Ｈｒｔのための低用量固体経口投与形態
JP5820465B2 (ja)	2010-04-15	2015-11-24	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	Ｈｒｔのための極低用量固体経口投与形態
WO2012120365A1 (en)	2011-03-07	2012-09-13	Aurobindo Pharma Limited	Stable pharmaceutical composition comprising ethinyl estradiol
EP2383279A1 (en)	2011-07-19	2011-11-02	Pantarhei Bioscience B.V.	Process for the preparation of estetrol
US8586527B2 (en)	2011-10-20	2013-11-19	Jaipal Singh	Cerivastatin to treat pulmonary disorders
CN102512688A (zh) *	2011-12-29	2012-06-27	上海新华联制药有限公司	尼尔雌醇-β-环糊精包合物及制剂和制备方法
LT2806877T (lt)	2012-01-23	2019-12-10	Sage Therapeutics Inc	Neuroaktyvios steroidų kompozicijos, apimančios alopregnanolono ir sulfobutilo eterio beta-ciklodekstrino kompleksą
RU2494757C1 (ru) *	2012-04-12	2013-10-10	Леонид Леонидович Клопотенко	Фармацевтическая композиция, содержащая фермент дезоксирибонуклеазу, альфа-фетопротеин и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
WO2013172969A1 (en)	2012-05-15	2013-11-21	The Uab Research Foundation	Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
HRP20220005T1 (hr)	2012-08-21	2022-04-01	Sage Therapeutics, Inc.	Alopregnanolon za liječenje refraktornog epileptičnog statusa
JOP20200195A1 (ar)	2014-09-08	2017-06-16	Sage Therapeutics Inc	سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US10888518B2 (en)	2015-06-18	2021-01-12	Estetra Sprl	Orodispersible tablet containing estetrol
MA45276A (fr)	2015-06-18	2018-04-25	Sage Therapeutics Inc	Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
RS61812B1 (sr)	2015-06-18	2021-06-30	Estetra Sprl	Oralno-disperzibilna tableta koja sadrži estetriol
RS57328B1 (sr)	2015-06-18	2018-08-31	Mithra Pharmaceuticals S A	Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu
CA2988495C (en) *	2015-06-18	2022-02-08	Mithra Pharmaceuticals S.A.	Orodispersible dosage unit containing an estetrol component
RU2640081C1 (ru) *	2016-07-11	2017-12-26	Общество с ограниченной ответственностью "ЛАЙФ САЙНСЕС ОХФК"	Фармацевтическая композиция и лекарственное средство на основе клатратного комплекса N-карбамоилметил-4-фенил-2-пирролидон или 4-фенилпирацетам с циклодекстрином, способы его получения (варианты)
KR20220144885A (ko)	2016-08-05	2022-10-27	에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼	월경통 및 생리통의 관리방법
TWI801561B (zh)	2018-04-19	2023-05-11	比利時商依思特拉私人有限責任公司	化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar)	2018-04-19	2019-10-19	Estetra Sprl	مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
EP3666260A1 (en)	2018-12-13	2020-06-17	Laboratorios Leon Farma SA	Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof
CN114225050B (zh) *	2022-01-29	2022-12-13	国家卫生健康委科学技术研究所	炔雌醇环糊精复合物的制备及应用
CN116617157A (zh) *	2023-05-25	2023-08-22	国家卫生健康委科学技术研究所	一种制备pH响应性炔雌醇复合水凝胶的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4154820A (en) *	1976-02-23	1979-05-15	Akzona Incorporated	Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
DE2652761C2 (de)	1976-11-16	1985-11-21	Schering AG, 1000 Berlin und 4709 Bergkamen	15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
JPS5527558A (en) *	1978-08-18	1980-02-27	Tokico Ltd	Gas spring
HU190356B (en)	1981-10-27	1986-08-28	Richter Gedeon Vegyeszeti Termekek Gyara Rt,Hu	Process for preparing steroid-gamma-cyclodextrin inclusion complexes with high water-solubility
US4383992A (en)	1982-02-08	1983-05-17	Lipari John M	Water-soluble steroid compounds
US4727064A (en) *	1984-04-25	1988-02-23	The United States Of America As Represented By The Department Of Health And Human Services	Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) *	1984-04-25	1986-06-24	The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services	Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727077A (en) *	1985-02-20	1988-02-23	Ishihara Sangyo Kaisha Ltd.	Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
US4877774A (en)	1987-09-09	1989-10-31	The United States Of America As Represented By The Department Of Health And Human Services	Administration of steroid hormones
NL8801670A (nl) *	1988-07-01	1990-02-01	Walter Adrianus Josephus Johan	Farmaceutisch preparaat.
US5229370A (en)	1988-08-15	1993-07-20	Ammeraal Robert N	Water soluble branched beta cyclodextrin steroid complex
DE3916112A1 (de)	1989-05-16	1990-11-22	Schering Ag	Dihydrospirorenon als antiandrogen
US4978532A (en) *	1989-08-11	1990-12-18	Pharmedic Co.	Dosage form for administration of dehydroepiandrosterone
JP3207212B2 (ja)	1991-03-01	2001-09-10	久光製薬株式会社	吸収促進剤およびこれを含有する外用剤
US5324718A (en) *	1992-07-14	1994-06-28	Thorsteinn Loftsson	Cyclodextrin/drug complexation
US5472954A (en) *	1992-07-14	1995-12-05	Cyclops H.F.	Cyclodextrin complexation
DE4426709A1 (de) *	1994-07-20	1996-01-25	Schering Ag	Steroidale Sexualhormone enthaltende feste Arzneiformen
AU700645B2 (en) *	1994-09-22	1999-01-14	N.V. Organon	Process of making dosage units by wet granulation
JP2920611B2 (ja)	1995-12-11	1999-07-19	株式会社シーエーシー	皮膚炎の治療外用剤
ES2223081T3 (es) *	1996-07-26	2005-02-16	Wyeth	Metodo anticonceptivo oral monofasico y kit que comprende una combinacion de progestina y estrogeno.
IL128632A (en) *	1996-08-22	2003-03-12	Rtp Pharma Corp	Compositions comprising microparticles of water-insoluble substances and method for preparing same
DE19652196A1 (de) *	1996-12-16	1998-06-18	Jenapharm Gmbh	Homogene steroidhaltige Präformulierungen zur Herstellung niedrigdosierter fester und halbfester pharmazeutischer Zubereitungen
DE19654609A1 (de)	1996-12-20	1998-06-25	Schering Ag	Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
DE19848303A1 (de) *	1998-10-14	2000-04-20	Schering Ag	Kombination aus Gestagenen und Zuckern
DE60007576D1 (de) *	1999-03-18	2004-02-12	Bristol Myers Squibb Co	Vitamin Formulierung für kardiovaskuläre Gesundheit
JP2000336032A (ja) *	1999-05-26	2000-12-05	Kissei Pharmaceut Co Ltd	ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物
EP1214076B1 (en) *	1999-08-31	2003-11-19	Schering Aktiengesellschaft	Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
SI1257280T1 (sl) *	2000-01-18	2006-02-28	Schering Ag	Farmacevtska kombinacija mikroniziranega drospirenona za hormonsko nadomestno terapijo

2000
- 2000-12-20 EP EP00610135A patent/EP1216713A1/en not_active Withdrawn
2001
- 2001-12-20 BR BRPI0116417-1 patent/BRPI0116417B8/pt not_active IP Right Cessation
- 2001-12-20 SI SI200130453T patent/SI1353700T1/sl unknown
- 2001-12-20 RS RS20090299A patent/RS57801B1/sr unknown
- 2001-12-20 CZ CZ2015-831A patent/CZ307876B6/cs not_active IP Right Cessation
- 2001-12-20 IL IL15643701A patent/IL156437A0/xx active IP Right Grant
- 2001-12-20 NZ NZ526847A patent/NZ526847A/en not_active IP Right Cessation
- 2001-12-20 EA EA200600884A patent/EA011275B1/ru not_active IP Right Cessation
- 2001-12-20 CN CNB018210880A patent/CN1268396C/zh not_active Expired - Lifetime
- 2001-12-20 KR KR1020087028897A patent/KR20080108161A/ko not_active Application Discontinuation
- 2001-12-20 CA CA2432151A patent/CA2432151C/en not_active Expired - Lifetime
- 2001-12-20 EP EP01271231A patent/EP1353700B1/en not_active Expired - Lifetime
- 2001-12-20 US US10/022,845 patent/US6958326B2/en not_active Expired - Lifetime
- 2001-12-20 RS YUP-512/03A patent/RS50362B/sr unknown
- 2001-12-20 WO PCT/IB2001/002605 patent/WO2002049675A1/en active Application Filing
- 2001-12-20 KR KR10-2003-7008216A patent/KR20030070905A/ko not_active Application Discontinuation
- 2001-12-20 MX MXPA03005636A patent/MXPA03005636A/es active IP Right Grant
- 2001-12-20 ES ES05077665.7T patent/ES2639537T3/es not_active Expired - Lifetime
- 2001-12-20 DK DK01271231T patent/DK1353700T3/da active
- 2001-12-20 CA CA2756207A patent/CA2756207C/en not_active Expired - Lifetime
- 2001-12-20 SK SK914-2003A patent/SK287500B6/sk not_active IP Right Cessation
- 2001-12-20 LT LTEP05077665.7T patent/LT1632237T/lt unknown
- 2001-12-20 AU AU1941802A patent/AU1941802A/xx active Pending
- 2001-12-20 SI SI200131065T patent/SI1632237T1/sl unknown
- 2001-12-20 ME MEP-381/08A patent/MEP38108A/xx unknown
- 2001-12-20 HU HU0302499A patent/HU230299B1/hu unknown
- 2001-12-20 JP JP2002551012A patent/JP4782364B2/ja not_active Expired - Lifetime
- 2001-12-20 KR KR1020097023221A patent/KR101275372B1/ko active IP Right Grant
- 2001-12-20 AT AT01271231T patent/ATE311204T1/de active
- 2001-12-20 DK DK05077665.7T patent/DK1632237T3/en active
- 2001-12-20 DE DE60115499T patent/DE60115499T2/de not_active Expired - Lifetime
- 2001-12-20 EP EP05077665.7A patent/EP1632237B1/en not_active Expired - Lifetime
- 2001-12-20 CZ CZ2003-1985A patent/CZ305671B6/cs not_active IP Right Cessation
- 2001-12-20 AU AU2002219418A patent/AU2002219418B2/en not_active Expired
- 2001-12-20 EE EEP200300298A patent/EE05282B1/et unknown
- 2001-12-20 EA EA200300669A patent/EA007411B1/ru not_active IP Right Cessation
- 2001-12-20 HU HU1500492A patent/HU230745B1/hu unknown
- 2001-12-20 ES ES01271231T patent/ES2249387T3/es not_active Expired - Lifetime
2003
- 2003-06-12 IL IL156437A patent/IL156437A/en unknown
- 2003-06-19 NO NO20032805A patent/NO332726B1/no not_active IP Right Cessation
- 2003-07-18 BG BG108002A patent/BG66050B1/bg unknown
- 2003-07-21 HR HR20030592A patent/HRP20030592B1/xx not_active IP Right Cessation
- 2003-10-28 HK HK03107767A patent/HK1055397A1/xx not_active IP Right Cessation
2005
- 2005-04-11 US US11/102,681 patent/US7163931B2/en not_active Expired - Lifetime
2006
- 2006-02-28 CY CY20061100281T patent/CY1106071T1/el unknown
- 2006-10-04 AU AU2006225232A patent/AU2006225232B8/en not_active Expired
- 2006-12-04 US US11/607,919 patent/US7569557B2/en not_active Expired - Lifetime
2007
- 2007-05-08 HR HRP20070198AA patent/HRP20070198B1/hr not_active IP Right Cessation
- 2007-12-19 IL IL188250A patent/IL188250A/en active IP Right Grant
2009
- 2009-02-05 JP JP2009025258A patent/JP5015976B2/ja not_active Expired - Lifetime
2017
- 2017-09-20 CY CY20171100996T patent/CY1119806T1/el unknown

Also Published As

Publication number	Publication date
EP1353700A1 (en)	2003-10-22
HUP0302499A2 (hu)	2003-11-28
EA007411B1 (ru)	2006-10-27
JP2009102424A (ja)	2009-05-14
HRP20030592B1 (en)	2007-05-31
ES2639537T3 (es)	2017-10-27
US20050182024A1 (en)	2005-08-18
IL156437A0 (en)	2004-01-04
HK1055397A1 (en)	2004-01-09
SK9142003A3 (en)	2004-03-02
IL188250A0 (en)	2008-03-20
CA2432151A1 (en)	2002-06-27
CN1268396C (zh)	2006-08-09
SI1632237T1 (sl)	2017-10-30
BR0116417A (pt)	2003-12-30
RS57801B1 (sr)	2018-12-31
DE60115499T2 (de)	2006-08-10
BRPI0116417B1 (pt)	2019-04-02
HRP20030592A2 (en)	2005-06-30
EP1353700B1 (en)	2005-11-30
IL188250A (en)	2012-02-29
SI1353700T1 (sl)	2006-02-28
JP5015976B2 (ja)	2012-09-05
CA2756207A1 (en)	2002-06-27
CY1106071T1 (el)	2011-06-08
HU230745B1 (hu)	2018-01-29
NO20032805D0 (no)	2003-06-19
HU230299B1 (hu)	2015-12-28
US20020173487A1 (en)	2002-11-21
BG108002A (bg)	2004-08-31
PL361799A1 (en)	2004-10-04
EA011275B1 (ru)	2009-02-27
DE60115499D1 (de)	2006-01-05
CY1119806T1 (el)	2018-06-27
HUP0302499A3 (en)	2012-02-28
CA2756207C (en)	2014-02-11
ATE311204T1 (de)	2005-12-15
AU2006225232A1 (en)	2006-10-26
DK1353700T3 (da)	2006-03-20
CZ305671B6 (cs)	2016-02-03
RS50362B (sr)	2009-11-10
NZ526847A (en)	2005-01-28
JP4782364B2 (ja)	2011-09-28
NO20032805L (no)	2003-08-20
CZ20031985A3 (cs)	2003-11-12
KR101275372B1 (ko)	2013-06-14
KR20090120015A (ko)	2009-11-23
AU2002219418C1 (en)	2002-07-01
ES2249387T3 (es)	2006-04-01
LT1632237T (lt)	2017-10-10
EP1632237A2 (en)	2006-03-08
HRP20070198A2 (en)	2007-09-30
CZ307876B6 (cs)	2019-07-10
AU2006225232B8 (en)	2007-11-15
NO332726B1 (no)	2012-12-27
WO2002049675A1 (en)	2002-06-27
HUP1500492A2 (en)	2003-11-28
KR20030070905A (ko)	2003-09-02
YU51203A (sh)	2006-08-17
MEP38108A (en)	2011-02-10
RS20090299A (en)	2009-11-10
HRP20070198B1 (hr)	2019-04-19
CN1482921A (zh)	2004-03-17
CZ2015831A3 (et)	2003-11-12
EA200300669A1 (ru)	2004-02-26
KR20080108161A (ko)	2008-12-11
DK1632237T3 (en)	2017-09-25
SK287500B6 (sk)	2010-12-07
EE200300298A (et)	2003-12-15
BRPI0116417B8 (pt)	2021-05-25
EP1632237A3 (en)	2006-04-12
US20070093451A1 (en)	2007-04-26
US7569557B2 (en)	2009-08-04
AU1941802A (en)	2002-07-01
AU2002219418B2 (en)	2006-07-06
BG66050B1 (bg)	2010-12-30
US7163931B2 (en)	2007-01-16
EA200600884A1 (ru)	2006-10-27
JP2004518656A (ja)	2004-06-24
MXPA03005636A (es)	2003-10-06
AU2006225232B2 (en)	2007-09-27
IL156437A (en)	2008-03-20
CA2432151C (en)	2012-01-24
EP1216713A1 (en)	2002-06-26
EP1632237B1 (en)	2017-06-21
US6958326B2 (en)	2005-10-25

Legal Events

Date	Code	Title	Description
2009-12-15	HC1A	Change of owner name
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2012-10-15	HC1A	Change of owner name
2013-12-16	GB1A	Change in the ownership or in the address of the owner

Publication	Publication Date	Title
EE05282B1 (et)	2010-04-15	strogeeni-tsklodekstriini komplekside kompositsioonid
DE60112609D1 (en)	2005-09-15	Pyrazolopyridine
HK1046403A1 (en)	2003-01-10	Nematicidal trifluorobutenes.
AU3652102A (en)	2002-06-11	Compounds and their uses
DE60112330D1 (en)	2005-09-01	Pyrazolopyridinderivate
MXPA02012891A (es)	2003-10-24	Composiciones farmaceuticas de agentes estrogenicos.
GB0011203D0 (en)	2000-06-28	Chemical compounds
MXPA04003886A (es)	2004-07-08	Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
MXPA02012493A (es)	2003-04-25	1-aril-4-oxo, 1,4-dihidro-3-quinolincarboxamidas como agentes antivirales.
CY1105798T1 (el)	2011-02-02	Στepοειδη, η παρασκευη τους, φαρμακευτικες συνθεσεις απο αυτα και χρησεις των ενωσεων
PT1107793E (pt)	2005-02-28	Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
MXPA03011128A (es)	2004-03-19	Composicion de sabor y fragancia.
AU2002248531A1 (en)	2002-09-24	Pyrazolopyriadine derivatives
SE9904128D0 (sv)	1999-11-15	Novel compounds
MD1473G2 (ro)	2001-05-31	Remediu antiherpetic
SE0001631D0 (sv)	2000-05-04	New use
ATE364619T1 (de)	2007-07-15	Tibolonformulierungen
DE60102704D1 (de)	2004-05-13	Trioxepan verbindungen
MEP38208A (en)	2011-02-10	COMPOSITION CONTAINING AN ANDROGENOUS 11beta-HALOGEN STEROID AND A PROGESTATIONAL HORMONE, AND MALE CONTRACEPTIVE BASED ON SAID COMPOSITION

EE05282B1 - strogeeni-tsklodekstriini komplekside kompositsioonid - Google Patents